Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

New Medications, New Digital Tools, New Criteria

Advances in science continue to provide new treatments for all types of medical conditions including those of high-need consumers with behavioral and cognitive conditions. In 2021, there were 50 new drugs approved by the Food and Drug Administration (FDA) (see Novel Drug Approvals for 2021). And, adding to the treatment options—there are eight approved digital therapies—Endeavor Rx, EaseVRx, Luminopia, One Mahana, Nightware, reSET, reSET-O, and Somryst (see What Are Digital Therapeutics?).

The question for executive teams of behavioral health and primary care provider organizations is when and how to use these new treatments to improve consumer . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!